Yanfen Liu
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia.
Journal: Clinical and experimental rheumatology
Published: April 08, 2025
Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.
Journal: Frontiers in immunology
Published: September 30, 2024
PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 13, 2024
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.
Journal: Cancer immunology, immunotherapy : CII
Published: December 09, 2021
Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.
Journal: Cytotherapy
Published: August 04, 2021
Elevated linc00936 or silenced microRNA-425-3p inhibits immune escape of gastric cancer cells via elevation of ZC3H12A.
Journal: International immunopharmacology
Published: September 09, 2020
ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.
Journal: Cell death & disease
Published: February 26, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026